U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49, the S&P 500 gaining 0.5% to 6,591.90 and the Nasdaq advancing 0.77% to 21,929.82.These are the top stocks that gained the attention of retail traders and investors through the day:Urban-gro’s stock skyrocketed by 416.95%, closing at $36.29. The stock reached an intraday high of $36.30 and a low of $7.40, setting a new 52-week high at $36.30. In the after-hours trading, the stock fell 19.65% to $29.16. The su ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Promising Early Data From Sarepta ProgramsSarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.Early results from the Phase 1/2 trials showed dose-dependent muscle exposure and favorable tolerability, reinforcing confidence in the potential of these investigational treatments.The company highlighted that both SRP- ...

Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St. S&P 5006,620.60 +0.16% Dow Jones46,616.80 +0.29% Nasdaq 10024,277.00 +0.17% Russell 20002,539.42 +0.09% FTSE 10010,096.40 +0.80% Nikkei 22553,855.50 +0.89% Stock Market Live March 25, 2026: S&P 500 (SPY) Roller Coaster Ride Continues Investing Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? AI Portfolio By David MoadelPublished Mar 25, ...

Sarepta Therapeutics (NasdaqGS:SRPT) Update / briefing March 25, 2026 08:30 AM ET Company ParticipantsAndrew Tsai - Managing DirectorBrian Abrahams - Head of Biotechnology ResearchDoug Ingram - CEOGavin Clark-Gartner - Managing DirectorJames Richardson - Chief Medical OfficerJoshua Fleischman - Biotech Equity Research AssociateKostas Biliouris - Managing Director of Biotech ResearchKuan-Hung Lin - Biotechnology Equity Research AssociateLouise Rodino-Klapac - President of R&D and Technical OperationsMike Ulz ...

Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerability, reinforcing scientific confidence in the potential for differentiated benefits of the v6 integrin-targeted delivery platform. In addition, the Company has generated proof-of-concept data which found that after a single dose, both SRP-1001 and ...

Key Takeaways Sarepta plans sNDAs to shift Amondys 45 and Vyondys 53 from accelerated to full approval.SRPT will submit real-world and clinical data after a study missed its primary endpoint.SRPT cited COVID-19 impact on results and highlighted favorable safety in the ESSENCE study.Sarepta Therapeutics (SRPT) announced plans to submit supplementary new drug applications (sNDAs) to the FDA for its two RNA-based PMO therapies — Amondys 45 and Vyondys 53 — by the end of next month. These filings seek to conver ...

Sarepta Seeks Regular FDA ApprovalsThe stock’s decline comes as the company plans to submit supplemental new drug applications to the U.S. Food and Drug Administration (FDA) by the end of April, as detailed in the regulatory update.Sarepta requested a meeting with the FDA to discuss submitting supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) to traditional approvals.Sarepta received FDA confirmation that it can s ...

Key Takeaways SRPT stock rose nearly 2% as enrollment began in cohort 8 of the phase Ib ENDEAVOR study.Sarepta tests sirolimus regimen to reduce Elevidys-related liver risks in non-ambulatory DMD patients.SRPT targets 25 patients, studying dose timings to address safety concerns after prior liver-related deaths.Shares of Sarepta Therapeutics (SRPT) rose about 2% yesterday after it announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study.This cohort is designed to impro ...